Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in cutting COPD attacks for former smokers

NCT ID NCT04701983

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new antibody drug called itepekimab in over 1,100 former smokers with moderate-to-severe COPD. The goal was to see if it could reduce the number of sudden worsening episodes (exacerbations) and improve breathing. Participants received either the drug or a placebo by injection, and researchers tracked their lung function and symptoms over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,127 people

The number who actually took part.

Started

Dec 2020

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * Participant must be 40 to 85 years of age inclusive. * Physician diagnosis of COPD for at least 1 year (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition). * Smoking history of ≥10 pack-years, but who are not currently smoking, and smoking cessation must have occurred ≥6 months prior to Screening (Visit 1A) with an intention to quit permanently. * Participants with moderate-to-severe COPD * Participant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year prior to screening in a participant in whom other causes of chronic cough \[eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis\] has been excluded). * Documented history of high exacerbation risk defined as having had ≥2 moderate or ≥1 severe exacerbations within the year prior to Screening (Visit 1A), with at least 1 exacerbation treated with systemic corticosteroids. At least one exacerbation must have occurred while participants were on their current controller therapy: * Moderate exacerbations will be recorded by the Investigator and are defined as acute worsening of respiratory symptoms that requires either systemic corticosteroids (IM, IV, or oral) and/or antibiotics. * Severe exacerbations will be recorded by the Investigator and are defined as AECOPD that require hospitalization or observation for \>24 hours in emergency department/urgent care facility. * Participants with standard of care controller therapy, for ≥3 months prior to Screening (Visit 1A) and at a stable dose of controller therapy for at least 1 month prior to the screening, including either: inhaled corticosteroid (ICS) + long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA) + LABA or LAMA + LABA + ICS. * Body mass index (BMI) ≥18.0 kg/m\^2, or BMI ≥16.0 kg/m\^2 for participants enrolled in East-Asian countries. * Female participant is not pregnant, not breastfeeding, and at least one of the following conditions applies: * not a women of child-bearing potential (WOCBP) OR * a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention. Exclusion criteria: * Current diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines, or documented history of asthma unless asthma resolved before 18 years of age and has not recurred. * Active smoking or vaping of any products (eg, nicotine, tetrahydrocannabinol \[THC\]) within 6 months prior to Screening (Visit 1A). * Clinically significant new abnormal electrocardiogram (ECG) within 6 months prior to, or at Screening (Visit 1A) that may affect the participant's participation in the study. * Clinically significant and current pulmonary disease other than COPD, eg, sarcoidosis, interstitial lung disease, bronchiectasis (clinical diagnosis), diagnosis of α-1 anti-trypsin deficiency, or another diagnosed pulmonary disease. * Diagnosis of cor pulmonale, evidence of right cardiac failure, or moderate-to-severe pulmonary hypertension. * Hypercapnia requiring bilevel positive airway pressure (BiPAP). * Moderate or severe exacerbation of COPD (AECOPD) within 4 weeks prior to Screening (Visit 1A). * Prior history of / planned: lung pneumonectomy for any reason, or lung volume reduction procedures (including bronchoscopic volume reduction) for COPD. Note: Surgical biopsy, or segmentectomy, or wedge resection, or lobectomy for other diseases would not be excluded. * Unstable ischemic heart disease, including acute myocardial infarction within the past 1 year prior to Screening, or unstable angina in the 6 months prior to Screening (Visit 1A). * Cardiac arrhythmias including paroxysmal (eg, intermittent) atrial fibrillation. * Uncontrolled hypertension (ie, systolic blood pressure \[BP\] \>180 mm Hg or diastolic BP \>110 mm Hg with or without use of anti-hypertensive therapy). * Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection (TBI), or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1A). * History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Screening (Visit 1A). * Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or in contact with known exposure to COVID-19 at Screening (Visit 1A); known history of COVID-19 infection within 4 weeks prior to Screening (Visit 1A); history of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to sScreening (Visit 1A); participants who have had a COVID-19 infection prior Screening (Visit 1A) who have not yet sufficiently recovered to participate in the procedures of a clinical trial. * Evidence of acute or chronic infection requiring systemic treatment with antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 4 weeks before Screening (Visit 1A), significant viral infections within 4 weeks before Screening (Visit 1A) that may not have been treated with antiviral treatment (eg, influenza receiving only symptomatic treatment). * Participants with active autoimmune disease or participants using immunosuppressive therapy for autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis. * History of malignancy within 5 years before Screening (Visit 1A), except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin. * Previous use of itepekimab. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • ASHA Clinical Research Site Number : 8400408

    Hammond, Indiana, 46324, United States

  • Accellacare Site Number : 8400001

    Wilmington, North Carolina, 28401, United States

  • AdtreMed Site Number : 8400442

    Tampa, Florida, 33607, United States

  • Advance Lung and Sleep Center Site Number : 8400040

    Sherman, Texas, 75092, United States

  • Advanced Clinical Research Site Number : 8400409

    Kendall, Florida, 33156, United States

  • Advanced Pulmonary Research Institute Site Number : 8400455

    Loxahatchee Groves, Florida, 33470, United States

  • Advanced Pulmonary Research Institute of Michigan Site Number : 8400403

    Warren, Michigan, 48088, United States

  • Alpha Clinical Research Georgia Site Number : 8400190

    Dunwoody, Georgia, 30350, United States

  • Antelope Valley Clinical Trials Site Number : 8400003

    Northridge, California, 91325, United States

  • Appalachian Clinical Research Site Number : 8400024

    Adairsville, Georgia, 30103, United States

  • Austin Pulmonary Consultants Site Number : 8400035

    Cedar Park, Texas, 78641, United States

  • Avanza Medical Research Center Site Number : 8400376

    Pensacola, Florida, 32503, United States

  • Beautiful Minds Clinical Research Center Site Number : 8400037

    Cutler Bay, Florida, 33157, United States

  • Benchmark Research Site Number : 8400193

    Covington, Louisiana, 70433, United States

  • Bernstein Clinical Research Center Site Number : 8400014

    Cincinnati, Ohio, 45236, United States

  • Biopharma Informatic - Cardiff Avenue - PPDS Site Number : 8400038

    Houston, Texas, 77043-2742, United States

  • Bogan Sleep Consultants Site Number : 8400181

    Columbia, South Carolina, 29201, United States

  • Broward Pulmonary and Sleep Specialists Site Number : 8400031

    Plantation, Florida, 33324, United States

  • California Research Institute Site Number : 8400400

    Huntington Park, California, 90255, United States

  • Care Access Site Number : 8400276

    Boston, Massachusetts, 02110, United States

  • Care Access Site Number : 8400277

    Boston, Massachusetts, 02110, United States

  • Care Access Site Number : 8400278

    Boston, Massachusetts, 02110, United States

  • Care Access Site Number : 8400280

    Boston, Massachusetts, 02110, United States

  • Care Access Site Number : 8400281

    Boston, Massachusetts, 02110, United States

  • Carolina Research Center Site Number : 8400005

    Shelby, North Carolina, 28150, United States

  • Chandler Clinical Trials (Elite Clinical Network) Site Number : 8400034

    Chandler, Arizona, 85286, United States

  • Clearlake Specialties Site Number : 8400025

    Webster, Texas, 77598, United States

  • Clin Research W Florida Site Number : 8400004

    Clearwater, Florida, 33765, United States

  • Clincove: Plano Primary Care Clinic Site Number : 8400424

    Plano, Texas, 75024, United States

  • Clinical Research of Central PA Site Number : 8400023

    DuBois, Pennsylvania, 15801, United States

  • Clinical Research of Rock Hill Site Number : 8400008

    Rock Hill, South Carolina, 29732, United States

  • Clinrx Research Site Number : 8400021

    Carrollton, Texas, 75007, United States

  • Coastal Medical Research Institute Site Number : 8400044

    St. Petersburg, Florida, 33707, United States

  • Corsicana Medical Research, LLC Site Number : 8400018

    Corsicana, Texas, 75110, United States

  • Covenant Pulmonary Critical Care Site Number : 8400183

    Atlanta, Georgia, 30344, United States

  • DL Research Solutions Inc Site Number : 8400033

    Miami, Florida, 33155, United States

  • DM Clinical Research Site Number : 8400179

    Tomball, Texas, 77375, United States

  • David Kavtaradze MD, Inc. Site Number : 8400029

    Cordele, Georgia, 31015, United States

  • Deluxe Health Center Site Number : 8400188

    Miami Lakes, Florida, 33014, United States

  • Downtown LA Research Center Inc. Site Number : 8400027

    Los Angeles, California, 90017, United States

  • EPW Curesearch Dallas (Advanced Family Medical Care) Site Number : 8400414

    Plano, Texas, 75093, United States

  • East Carolina University Brody School Of Medicine Site Number : 8400022

    Greenville, North Carolina, 27834, United States

  • Exordia Medical Research, Inc. Site Number : 8400041

    Fall River, Massachusetts, 02723, United States

  • Florida Institute for Clinical Research Site Number : 8400013

    Orlando, Florida, 32825-4454, United States

  • Gastonia Pharmaceutical Research Site Number : 8400010

    Gastonia, North Carolina, 28054, United States

  • GenHarp Clinical Solutions Site Number : 8400028

    Evergreen Park, Illinois, 60805, United States

  • Gwinnett Biomedical Research Site Number : 8400007

    Lawrenceville, Georgia, 30046, United States

  • Hannibal Clinic Site Number : 8400383

    Hannibal, Missouri, 63401, United States

  • Hendeson Clinical Trials Site Number : 8400365

    Henderson, Nevada, 89052, United States

  • High Quality Research Site Number : 8400406

    Miami, Florida, 33184, United States

  • Imax Clinical Trials LLC 1 Site Number : 8400419

    La Palma, California, 90623, United States

  • Indago Research and Health Center Site Number : 8400187

    Hialeah, Florida, 33012, United States

  • Innovative Clinical Research Site Number : 8400017

    Lafayette, Colorado, 80026, United States

  • Investigational Site Number : 0320001

    CABA, Buenos Aires, C1425BEN, Argentina

  • Investigational Site Number : 0320002

    CABA, Buenos Aires, C1425FVH, Argentina

  • Investigational Site Number : 0320003

    Rosario, Santa Fe Province, S2000DEJ, Argentina

  • Investigational Site Number : 0320004

    Mendoza, 5500, Argentina

  • Investigational Site Number : 0320005

    La Plata, Buenos Aires, B1900BNN, Argentina

  • Investigational Site Number : 1000001

    Sofia, 1233, Bulgaria

  • Investigational Site Number : 1000002

    Sofia, 1407, Bulgaria

  • Investigational Site Number : 1000003

    Stara Zagora, 6001, Bulgaria

  • Investigational Site Number : 1000004

    Sofia, 1233, Bulgaria

  • Investigational Site Number : 1000005

    Dimitrovgrad, 6400, Bulgaria

  • Investigational Site Number : 1000006

    Stara Zagora, 6000, Bulgaria

  • Investigational Site Number : 1000007

    Veliko Tarnovo, 5000, Bulgaria

  • Investigational Site Number : 1000008

    Vidin, 3700, Bulgaria

  • Investigational Site Number : 1000009

    Sofia, 1756, Bulgaria

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 7500692, Chile

  • Investigational Site Number : 1520002

    Talca, Maule Region, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, 7500571, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, 7750495, Chile

  • Investigational Site Number : 1520005

    Quillota, Valparaiso, 2260877, Chile

  • Investigational Site Number : 1520006

    Santiago, Reg Metropolitana de Santiago, 7500698, Chile

  • Investigational Site Number : 1520007

    Curicó, Maule Region, 3341643, Chile

  • Investigational Site Number : 1520008

    Temuco, La Araucanía, 4781173, Chile

  • Investigational Site Number : 1520009

    Santiago, Reg Metropolitana de Santiago, 7500010, Chile

  • Investigational Site Number : 1560001

    Chengdu, 610041, China

  • Investigational Site Number : 1560002

    Changchun, 130021, China

  • Investigational Site Number : 1560003

    Baotou, 014010, China

  • Investigational Site Number : 1560004

    Beijing, 100020, China

  • Investigational Site Number : 1560005

    Shenyang, 110004, China

  • Investigational Site Number : 1560006

    Guangzhou, 510150, China

  • Investigational Site Number : 1560007

    Xuzhou, 221002, China

  • Investigational Site Number : 1560008

    Hohhot, 010017, China

  • Investigational Site Number : 1560009

    Shanghai, 200433, China

  • Investigational Site Number : 1560010

    Hohhot, 010050, China

  • Investigational Site Number : 1560012

    Changsha, 410011, China

  • Investigational Site Number : 1560013

    Changsha, 410013, China

  • Investigational Site Number : 1560014

    Beijing, China

  • Investigational Site Number : 1560015

    Pingxiang, 337055, China

  • Investigational Site Number : 1560016

    Xi'an, China

  • Investigational Site Number : 1560017

    Hefei, China

  • Investigational Site Number : 1560019

    Wenzhou, 325000, China

  • Investigational Site Number : 1560020

    Shenzhen, 518020, China

  • Investigational Site Number : 1560022

    Hangzhou, 310014, China

  • Investigational Site Number : 1560023

    Nanning, 530021, China

  • Investigational Site Number : 1560024

    Tianjin, 300052, China

  • Investigational Site Number : 1560025

    Guangzhou, 510163, China

  • Investigational Site Number : 1560026

    Yangzhou, 225001, China

  • Investigational Site Number : 1560027

    Jinan, 250014, China

  • Investigational Site Number : 1560028

    Shijiazhuang, 050000, China

  • Investigational Site Number : 1560029

    Wuhan, 430014, China

  • Investigational Site Number : 1560030

    Beijing, 100038, China

  • Investigational Site Number : 1560031

    Nanchang, 330006, China

  • Investigational Site Number : 1560032

    Chongqing, 400038, China

  • Investigational Site Number : 1560034

    Shanghai, 200240, China

  • Investigational Site Number : 1560035

    Nanjing, 210009, China

  • Investigational Site Number : 1560036

    Haikou, 570216, China

  • Investigational Site Number : 1560039

    Hangzhou, China

  • Investigational Site Number : 1560040

    Chengdu, 611130, China

  • Investigational Site Number : 1560041

    Zhanjiang, 524001, China

  • Investigational Site Number : 1560042

    Zhengzhou, 450008, China

  • Investigational Site Number : 1560043

    Shanghai, 200025, China

  • Investigational Site Number : 1560044

    Jinan, 250013, China

  • Investigational Site Number : 1560045

    Shanghai, China

  • Investigational Site Number : 1560046

    Xiangtan, 411100, China

  • Investigational Site Number : 1560047

    Changsha, 410023, China

  • Investigational Site Number : 1560048

    Zhongshan, 528403, China

  • Investigational Site Number : 1580002

    New Taipei City, 220, Taiwan

  • Investigational Site Number : 1580003

    Taipei, 11031, Taiwan

  • Investigational Site Number : 1580004

    Taipei, 10002, Taiwan

  • Investigational Site Number : 1580005

    Kaohsiung City, 807, Taiwan

  • Investigational Site Number : 1580006

    Taichung, 40447, Taiwan

  • Investigational Site Number : 1580008

    Yunlin, Taiwan

  • Investigational Site Number : 2030001

    Jindrichuv Hradec III, 37701, Czechia

  • Investigational Site Number : 2030002

    Prague, 140 46, Czechia

  • Investigational Site Number : 2030003

    Prague, 18200, Czechia

  • Investigational Site Number : 2030004

    Ostrava, 70800, Czechia

  • Investigational Site Number : 2030005

    Praha 5 - Radotin, 15300, Czechia

  • Investigational Site Number : 2030006

    Havlíčkův Brod, 580 01, Czechia

  • Investigational Site Number : 2680001

    Tbilisi, 159, Georgia

  • Investigational Site Number : 2680002

    Tbilisi, 0112, Georgia

  • Investigational Site Number : 2680003

    Tbilisi, 0112, Georgia

  • Investigational Site Number : 3000001

    Ioannina, 455 00, Greece

  • Investigational Site Number : 3000002

    Thessaloniki, 57010, Greece

  • Investigational Site Number : 3000004

    Heraklion, 71500, Greece

  • Investigational Site Number : 3000005

    Athens, 106 76, Greece

  • Investigational Site Number : 3000006

    Athens, 11527, Greece

  • Investigational Site Number : 3000007

    Larissa, 41110, Greece

  • Investigational Site Number : 3000008

    Palaio Faliro, Athens, 17562, Greece

  • Investigational Site Number : 3480001

    Gödöllö, 2100, Hungary

  • Investigational Site Number : 3480002

    Mosonmagyaróvár, 9200, Hungary

  • Investigational Site Number : 3480003

    Pécs, 7635, Hungary

  • Investigational Site Number : 3480004

    Debrecen, 4031, Hungary

  • Investigational Site Number : 3560001

    Kozhikode, 673008, India

  • Investigational Site Number : 3560002

    Coimbatore, 641028, India

  • Investigational Site Number : 3560003

    Nagpur, 441203, India

  • Investigational Site Number : 3560004

    Jaipur, 302039, India

  • Investigational Site Number : 3560005

    Hyderabad, 500 084, India

  • Investigational Site Number : 3560007

    Mumbai, 400078, India

  • Investigational Site Number : 3760001

    Petah Tikva, 49100, Israel

  • Investigational Site Number : 3760002

    Jerusalem, 91120, Israel

  • Investigational Site Number : 3760003

    Jerusalem, 91031, Israel

  • Investigational Site Number : 3760004

    Rehovot, 76100, Israel

  • Investigational Site Number : 3760006

    Kfar Saba, 44281, Israel

  • Investigational Site Number : 3760007

    Tel Aviv, 64239, Israel

  • Investigational Site Number : 3760008

    Haifa, 34362, Israel

  • Investigational Site Number : 3760009

    Ramat Gan, 5266202, Israel

  • Investigational Site Number : 3800001

    Ferrara, 44124, Italy

  • Investigational Site Number : 3800003

    Rozzano, Milano, 20089, Italy

  • Investigational Site Number : 3800004

    Foggia, Apulia, 71122, Italy

  • Investigational Site Number : 3800005

    Catania, 95123, Italy

  • Investigational Site Number : 3800007

    Verona, 37134, Italy

  • Investigational Site Number : 4800001

    Quatre Bornes, 72218, Mauritius

  • Investigational Site Number : 4840001

    Guadalajara, Jalisco, 44100, Mexico

  • Investigational Site Number : 4840002

    Mexico City, Mexico City, 06700, Mexico

  • Investigational Site Number : 4840003

    San Juan del Río, Querétaro, 76800, Mexico

  • Investigational Site Number : 4840004

    Benito Juárez, 03100, Mexico

  • Investigational Site Number : 4840007

    Cuernavaca, Morelos, 62250, Mexico

  • Investigational Site Number : 4840010

    Guadalajara, Jalisco, 44210, Mexico

  • Investigational Site Number : 4840011

    Guadalajara, Jalisco, 44130, Mexico

  • Investigational Site Number : 4840013

    Aguascalientes, 20116, Mexico

  • Investigational Site Number : 4840014

    Oaxaca City, 68000, Mexico

  • Investigational Site Number : 4840016

    Oaxaca City, Oaxaca, 68020, Mexico

  • Investigational Site Number : 6160001

    Bialystok, Podlaskie Voivodeship, 15-044, Poland

  • Investigational Site Number : 6160002

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 27-400, Poland

  • Investigational Site Number : 6160003

    Warsaw, Masovian Voivodeship, 02-777, Poland

  • Investigational Site Number : 6160004

    Wroclaw, Lower Silesian Voivodeship, 53-673, Poland

  • Investigational Site Number : 6420001

    Iași, 700732, Romania

  • Investigational Site Number : 6420002

    Cluj-Napoca, 400275, Romania

  • Investigational Site Number : 6420003

    Timișoara, 300134, Romania

  • Investigational Site Number : 6420005

    Bragadiru, 769764, Romania

  • Investigational Site Number : 6420006

    Brasov, 500450, Romania

  • Investigational Site Number : 6420007

    Codlea, 505100, Romania

  • Investigational Site Number : 6420009

    Oradea, 410155, Romania

  • Investigational Site Number : 6420010

    Deva, 330162, Romania

  • Investigational Site Number : 6420012

    Bucaresti, 010192, Romania

  • Investigational Site Number : 6430001

    Moscow, 115093, Russia

  • Investigational Site Number : 6430002

    Moscow, 117546, Russia

  • Investigational Site Number : 6430003

    Moscow, 115280, Russia

  • Investigational Site Number : 6430005

    Saint Petersburg, 194354, Russia

  • Investigational Site Number : 6430006

    Saint Petersburg, 194354, Russia

  • Investigational Site Number : 7030001

    Spišská Nová Ves, 05201, Slovakia

  • Investigational Site Number : 7030002

    Poprad, 058 01, Slovakia

  • Investigational Site Number : 7030003

    Levice, 93401, Slovakia

  • Investigational Site Number : 7030007

    Humenné, 066 01, Slovakia

  • Investigational Site Number : 7030009

    Bardejov, 08501, Slovakia

  • Investigational Site Number : 7030010

    Prešov, 08001, Slovakia

  • Investigational Site Number : 7030011

    Martin, 03659, Slovakia

  • Investigational Site Number : 8040001

    Kyiv, 01033, Ukraine

  • Investigational Site Number : 8040003

    Ivano-Frankivsk, 76018, Ukraine

  • Investigational Site Number : 8040004

    Kyiv, 01023, Ukraine

  • Investigational Site Number : 8040005

    Kyiv, 02091, Ukraine

  • Investigational Site Number : 8040006

    Kharkiv, 61166, Ukraine

  • Investigational Site Number : 8040007

    Ivano-Frankivsk, 76018, Ukraine

  • Investigational Site Number : 8040008

    Kharkiv, 61039, Ukraine

  • Investigational Site Number : 8040011

    Kyiv, 04050, Ukraine

  • Investigational Site Number : 8260001

    London, EC1M 6BQ, United Kingdom

  • Investigational Site Number : 8260003

    Bradford, BD9 6RJ, United Kingdom

  • Investigational Site Number : 8260004

    Portsmouth, Hampshire, PO6 3LY, United Kingdom

  • Investigational Site Number : 8260010

    Wigan, Lancashire, WN6 9EP, United Kingdom

  • Investigational Site Number : 8260013

    Redruth, TR16 4ET, United Kingdom

  • Investigational Site Number : 8260014

    Heston, TW5 9ER, United Kingdom

  • Investigational Site Number : 8260015

    Ashton-under-Lyne, Lancashire, OL69RW, United Kingdom

  • Investigational Site Number : 8260016

    Salford, Manchester, M6 8HD, United Kingdom

  • Jasper Summit Research Site Number : 8400178

    Jasper, Alabama, 35501, United States

  • MACRO Trials Site Number : 8400030

    Los Angeles, California, 90048, United States

  • Metroplex Pulmonary and Sleep Center Site Number : 8400015

    McKinney, Texas, 75069, United States

  • Midwest Chest Consultants, P.C. Site Number : 8400002

    Saint Charles, Missouri, 63301, United States

  • Modena Allergy + Asthma Site Number : 8400036

    La Jolla, California, 92037, United States

  • My Community Research Center Site Number : 8400347

    Miami, Florida, 33155, United States

  • Noble Clinical Research Site Number : 8400182

    Tucson, Arizona, 85704-7876, United States

  • Northwell Health Site Number : 8400019

    Mount Kisco, New York, 10549, United States

  • PROLIVE MEDICAL RESEARCH Site Number : 8400420

    Miami, Florida, 33175, United States

  • PRX Research Site Number : 8400380

    Mesquite, Texas, 75149, United States

  • Pasadena Center for Medical Research Site Number : 8400043

    St. Petersburg, Florida, 33710, United States

  • Paul Shapero, PC Site Number : 8400016

    Bangor, Maine, 04401, United States

  • Premier Medical Associates Site Number : 8400388

    The Villages, Florida, 32159, United States

  • Premier Pulmonary Critical Care and Sleep Medicine Site Number : 8400440

    Denison, Texas, 75020, United States

  • Pulmonary Associates Site Number : 8400392

    Phoenix, Arizona, 85027, United States

  • REX Clinical Trials Site Number : 8400371

    Beaumont, Texas, 77701, United States

  • Reed Medical Research Site Number : 8400032

    Miami, Florida, 33176, United States

  • Reliant Medical Research Site Number : 8400397

    Miami, Florida, 33165, United States

  • Research Institute of South Florida,Inc Site Number : 8400006

    Miami, Florida, 33173, United States

  • Revival Research Institute, LLC Site Number : 8400191

    Dearborn, Michigan, 48126, United States

  • Santa Clara Family Clinic Site Number : 8400398

    Houston, Texas, 77087, United States

  • Sherman Clinical Research Site Number : 8400009

    Sherman, Texas, 75092, United States

  • Southeastern Research Center Site Number : 8400011

    Winston-Salem, North Carolina, 27103, United States

  • Tellabio International Research Services Site Number : 8400411

    Pembroke Pines, Florida, 33025, United States

  • Texas Tech University Health Sciences Center Site Number : 8400189

    El Paso, Texas, 79911, United States

  • The Lung and Sleep Research Institute of North Texas Site Number : 8400417

    North Richland Hills, Texas, 76180, United States

  • The Methodist Hospital Research Institute Site Number : 8400194

    Houston, Texas, 77030, United States

  • Tucson Clinical Research Institute Site Number : 8400431

    Tucson, Arizona, 85712, United States

  • University of Alabama at Birmingham Site Number : 8400012

    Birmingham, Alabama, 34294, United States

  • University of Miami/Miami VA Medical Center Site Number : 8400026

    Miami, Florida, 33125, United States

  • WellNow Urgent Care and Clinical Research Site Number : 8400378

    Schenectady, New York, 12304, United States

  • WellNow Urgent Care and Research Site Number : 8400039

    Springdale, Ohio, 45215, United States

  • ~Alpine Clinical Research Center Site Number : 8400180

    Boulder, Colorado, 80301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.